Nav: Home

Anti-inflammatory agents can effectively and safely curb major depressive symptoms

October 28, 2019

Anti-inflammatory agents, such as aspirin/paracetamol, statins, and antibiotics, can safely and effectively curb the symptoms of major depression, finds a pooled analysis of the available evidence, published online in the Journal of Neurology Neurosurgery & Psychiatry.

And the effects are even stronger when these agents are added on to standard antidepressant treatment, the results show.

Around a third of people who are clinically depressed don't respond well to current drug and talking therapies, and drug side effects are relatively common.

An emerging body of evidence suggests that inflammation contributes to the development of major depression, but the results of clinical trials using various anti-inflammatory agents to treat the condition have proved inconclusive.

The researchers therefore set out to review the available evidence and pool the data to see if anti-inflammatory agents work better than dummy (placebo) treatment either alone or when used as add-on therapy to standard antidepressant treatment.

Anti-inflammatory agents included: non-steroidal anti-inflammatory drugs (NSAIDs); omega 3 fatty acids; drugs that curb production of inflammatory chemicals (cytokine inhibitors); statins; steroids; antibiotics (minocyclines); a drug used to treat sleep disorders (modafinil); and N-acetyl cysteine, known as NAC, and used to loosen the excess phlegm of cystic fibrosis and COPD and also taken as an antioxidant supplement.

The researchers trawled research databases to find suitable studies published up to January 2019. They found 30 relevant randomised controlled trials, involving 1610 people, which reported changes in depression scales. They pooled the data from 26 of these studies.

The pooled data analysis suggested that anti-inflammatory agents were better than placebo and enhanced the effects of standard antidepressant treatment.

These agents were 52% more effective in reducing symptom severity, overall, and 79% more effective in eliminating symptoms than placebo, as measured by an average fall in depression scales of 55.

More detailed analysis indicated that NSAIDs, omega 3 fatty acids, statins, and minocyclines were the most effective at reducing major depressive symptoms compared with placebo.

And the effects were even greater when one or other of these agents was added to standard antidepressant treatment.

But anti inflammatory agents didn't seem to improve quality of life, although this might have been because of the small number of studies which looked at this aspect, say the researchers.

No major side effects were evident, although there were some gut symptoms among those taking statins and NACs, and the trials lasted only 4 to 12 weeks, so it wasn't possible to track side effects over the longer term.

The researchers also point out that not all studies tracked changes in depression scores over the entire study period. The depression scales used in the studies differed, and those involving statins and minocyclines included only small numbers of patients.

Nevertheless, they conclude: "The results of this systematic review suggest that anti-inflammatory agents play an antidepressant role in patients with major depressive disorder and are reasonably safe."
-end-
Peer reviewed? Yes

Evidence type: Systematic review; meta analysis

Subjects: People

BMJ

Related Statins Articles:

It is never too late to start statins for clogged leg arteries
Statins are linked with reduced mortality in patients with peripheral arterial disease, even when started late after diagnosis, reports a study presented today at ESC Congress 2019 together with the World Congress of Cardiology.
New cholesterol-lowering drug could help patients unable to take statins
A new class of oral cholesterol-lowering drug could help patients unable to take statins due to side effects.
Statins linked to higher diabetes risk
Individuals who take cholesterol-lowering statins may be at higher risk for developing high blood sugar levels, insulin resistance, and eventually type 2 diabetes, according to an analysis published in the British Journal of Clinical Pharmacology.
Statins could protect against motor neurone disease
High cholesterol has been found to be a possible risk factor for the development of motor neurone disease (MND), according to a large study of genetic data led in the UK by Queen Mary University of London, in collaboration with the National Institutes of Health in the USA.
Statins are more effective for those who follow the Mediterranean diet
For those who have already had a heart attack or a stroke, the combination of statins and Mediterranean Diet appears to be the most effective choice to reduce the risk of mortality, especially from cardiovascular causes.
Statins have low risk of side effects
Cholesterol-lowering statin drugs are associated with a low risk of side effects.
Statins overprescribed for primary prevention
Taking cholesterol-lowering drugs, or statins, as a preventive measure can reduce the risk of cardiovascular disease.
Many older adults do not take prescribed statins properly
In a British Journal of Clinical Pharmacology study of older adults prescribed statins, first-year nonadherence and discontinuation rates were high.
Statins show little promise for conditions other than heart disease
Medicines commonly prescribed to reduce people's risk of heart attack may have limited use for treating other diseases, research suggests.
Statins associated with improvement of rare lung disease
Researchers have found that cholesterol-lowering statins may improve the conditions of people with a rare lung disease called autoimmune pulmonary alveolar proteinosis.
More Statins News and Statins Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Accessing Better Health
Essential health care is a right, not a privilege ... or is it? This hour, TED speakers explore how we can give everyone access to a healthier way of life, despite who you are or where you live. Guests include physician Raj Panjabi, former NYC health commissioner Mary Bassett, researcher Michael Hendryx, and neuroscientist Rachel Wurzman.
Now Playing: Science for the People

#544 Prosperity Without Growth
The societies we live in are organised around growth, objects, and driving forward a constantly expanding economy as benchmarks of success and prosperity. But this growing consumption at all costs is at odds with our understanding of what our planet can support. How do we lower the environmental impact of economic activity? How do we redefine success and prosperity separate from GDP, which politicians and governments have focused on for decades? We speak with ecological economist Tim Jackson, Professor of Sustainable Development at the University of Surrey, Director of the Centre for the Understanding of Sustainable Propserity, and author of...
Now Playing: Radiolab

An Announcement from Radiolab